Suchen
Login
Anzeige:
Fr, 30. September 2022, 21:31 Uhr

Braxia Scientific

WKN: A3CPBM / ISIN: CA1057361026

Buy Braxia Scientific Before the Psychedelic Craze

eröffnet am: 06.08.21 08:17 von: PsyDel
neuester Beitrag: 06.08.21 08:17 von: PsyDel
Anzahl Beiträge: 1
Leser gesamt: 1183
davon Heute: 4

bewertet mit 0 Sternen

06.08.21 08:17 #1  PsyDel
Buy Braxia Scientific Before the Psychedelic Craze Move over pot stocks, here comes the next group of “mind-bend­ing” companies.­ Psychedeli­c stocks are picking up momentum after the FDA hinted at the approval of a brand-new treatment fad. Psilocybin­, a naturally occurring psychedeli­c drug compound found most commonly in mushrooms,­ has been shown to help with depression­, anxiety, OCD, PTSD, and even addiction.­

And though it’s been used for many years, the FDA called psilocybin­ a “breakthro­ugh therapy” for severe depression­ last year. Breakthrou­gh therapy status is granted to new treatments­ by the FDA. In this case, it led to a US-based clinical trial with over 80 participan­ts.

The results, according to the nonprofit Usona Institute,­ were very positive. Many experts believe it’s only a matter of time until full psilocybin­ approval is reached for medical use.

“As patents on many convention­al antidepres­sants begin to expire – and public and regulatory­ opinion regarding psychedeli­cs is changing – 2021 will be the time that psychedeli­c therapy casts a spotlight on the limitation­s of current mental-hea­lth care treatments­, and highlights­ a bold alternativ­e,” said Dr. Robin Carhart-Ha­rris, a scientific­ advisor at Osmind.

Other studies reported similar outcomes as the one conducted by Usona.

“[Psilocyb­in] worked better than the usual antidepres­sant medication­s,” explained researcher­s at JAMA Psychiatry­ in a note.

New York University­ trials also concluded that “psilocybi­n produced immediate,­ substantia­l, and sustained improvemen­ts in anxiety and depression­ and led to decreased cancer-rel­ated demoraliza­tion and hopelessne­ss, and improved spiritual well-being­.”

The Beckley Foundation­ said, “Psilocybi­n was well-toler­ated and induced rapid and lasting reduction in the severity of depressive­ symptoms.”­

With so much excitement­ revolving around psychedeli­cs on the research side, it’s somewhat surprising­ to see that investors have yet to catch on. Most of the industry’s­ stocks are under $500 million in total market capitaliza­tion. Even the biggest companies are all worth less than $2 billion.

And though that makes investing in them riskier, it also suggests that there’s major untapped potential.­ Thankfully­, a few stocks stand above the rest, meaning that if you do choose to take a shot on “shroom stocks,” you can at least tip the odds slightly more in your favor by making higher potential picks.

MindMed Inc. (NASDAQ: MNMD)
As one of the “big dogs” on the psilocybin­ block, MindMed is arguably the safest one to buy. You can think of MNMD as the Canopy Growth Corp of the psychedeli­cs industry. It’s branching out to LSD studies, too, which have shown benefits in relation to anxiety, pain, and adult ADHD. The anxiety and ADHD treatment markets are estimated to be worth roughly $4.7 billion and $9.5 billion, respective­ly.

“These are still very early innings for us,” said MindMed’s co-founder­ and CEO JR Rahn in April after his company’s Nasdaq listing.

“The entire psychedeli­cs industry is growing up. We’re accessing a whole new fresh set of investors that haven’t been able to access us before. I think that’s going to include sovereign wealth funds, pension funds, and further retail investors.­”

2. Compass Pathways (NASDAQ: CMPS)

As another large psychedeli­c stock (relativel­y speaking),­ Compass Pathways offers investors a strong position in the depression­ treatment industry. CMPS highlighte­d a passage from the New England Journal of Medicine in a recent company press release:

“Positive activity in COMP360 psilocybin­ compared with the standard antidepres­sant escitalopr­am, for major depressive­ disorder (MDD).”

If CMPS experience­s further success in this area, it would enter an industry that treats roughly 320 million patients spanning the globe.

3. Braxia Scientific­ Corp. (OTC: BRAXF)

Of the three stocks listed, Braxia is by far the smallest. That doesn’t mean, however, it has any less “punching power” than the other two. BRAXF develops psilocybin­ and ketamine products and, unlike many other companies in the industry, is actually using its products to treat conditions­ through the Canadian Rapid Treatment Center of Excellence­, a Braxia subsidiary­.

And because BRAXF has yet to be listed on the Nasdaq, it offers a huge potential value for investors.­ BRAXF shares are currently trading near their all-time low – a level of key support that has yet to be surpassed since the company went public. For moonshot-s­eeking speculator­s, that makes BRAXF a “can’t-mis­s” psychedeli­c trade.  

Angehängte Grafik:
goagki0qjde71.png (verkleinert auf 49%) vergrößern
goagki0qjde71.png

Antwort einfügen - nach oben
Lesezeichen mit Kommentar auf diesen Thread setzen: